For a company of its size, Bubs Australia (ASX:BUB) has generated an unusual amount of disclosure in a single fortnight. The infant nutrition group went into a Trading halt on 4 September 2026, emerged with news of permanent United States regulatory approval, ran an investor webinar on the subject and then answered a formal ASX query — all within a week. Bubs is a name where the American market access question has long sat at the centre of the Investment case.

Company Overview

Bubs Australia is an infant nutrition Business founded in 2006 and headquartered at Dandenong South in Victoria. It markets what it describes as clean nutrition for the first 1,000 days of life, with a range spanning A2 beta-casein protein formula, organic grass-fed cow milk formula, goat milk infant formula and organic baby food.

The listed entity has a long history on the exchange, having been quoted since 1993 under its former identity as Aurifex Mining NL before adopting the Bubs Australia name in 2016. Goat milk formula in particular has been a point of differentiation in a category dominated by far larger multinationals.

On 6 September 2026 Bubs announced that it had secured permanent US Food and Drug Administration approval for its infant formula, a price-sensitive release that followed the trading halt two days earlier. The company's investor centre carries the item dated 7 September 2026. Bubs moved quickly to explain it. A webinar notification was lodged on 8 September 2026 and the accompanying presentation on 9 September. On 10 September the company filed a response to an ASX aware query, itself flagged price sensitive — the exchange's standard mechanism when trading activity warrants an explanation.

Full-year reporting preceded the regulatory news. Bubs flagged the timing on 4 August 2026 and lodged its Appendix 4E preliminary final report on 27 August 2026, together with an FY26 results presentation and results commentary. The board also saw movement, with director's interest notices filed for Paul Jensen, Pascal De Petrini and Lori Tauber Marcus across 3 and 4 September 2026, immediately ahead of the halt.

Financial and Operational Position

Bubs has not paid a dividend. The word “permanent” in the September announcement is itself meaningful. It signals a shift in the basis on which Bubs may Supply the US market, from an arrangement that was not permanent to one that is — which bears directly on how durable American Revenue can be treated.

What Investors May Watch Next

The commercial translation of the approval is the item to track: retailer listings, distribution agreements and volumes actually shipped into the United States. Management commentary from the September webinar and any follow-up guidance may frame expectations. Quarterly updates and the next half-year result will show whether approval converts into sustained revenue rather than a one-off news event.

Risks

Regulatory clearance grants access, not market share; the US infant formula category is concentrated among established manufacturers with entrenched retail relationships. Bubs remains exposed to input costs, freight, currency and the cross-border China channels that have been volatile for Australian infant nutrition brands. Scaling supply into a larger market carries execution risk.

Key Takeaways

The key story for Bubs Australia this September is straightforward to identify and harder to value: permanent FDA approval removes a long-standing question mark over the company's largest growth market. Whether that changes the trajectory depends on commercial execution that has yet to be demonstrated. Investors may be watching the Volume and distribution disclosures that follow, rather than the approval itself.